Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation.

doi:10.1002/lt.24505

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society - 1 Oct 2016

Dumortier Jérôme, Leroy Vincent, Duvoux Christophe, de Ledinghen Victor, Francoz Claire, Houssel-Debry Pauline, Radenne Sylvie, d'Alteroche Louis, Fougerou-Leurent Claire, Canva Valérie, di Martino Vincent, Conti Filomena, Kamar Nassim, Moreno Christophe, Lebray Pascal, Tran Albert, Besch Camille, Diallo Alpha, Rohel Alexandra, Rossignol Emilie, Abergel Armand, Botta-Fridlund Danielle, Coilly Audrey, Samuel Didier, Duclos-Vallée Jean-Charles, Pageaux Georges-Philippe

Abstract excerpt

Recurrence of hepatitis C virus (HCV) after liver transplantation (LT) can rapidly lead to liver graft cirrhosis and, therefore, graft failure and retransplantation or death. The aim of the present study was to assess efficacy and tolerance of sofosbuvir (SOF)-based regimens for the treatment of HCV recurrence in patients with severe fibrosis after LT. The Compassionate Use of Protease Inhibitors in Viral C Liver...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Belgium

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carbamates

Share to Imidazoles

Share to Liver Transplantation

Share to Protease Inhibitors

Share to Pyrrolidines

Share to Reoperation

Share to Sofosbuvir

Source

Open in PubMed

Identifiers

PMID: 27348086
DOI: 10.1002/lt.24505

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation.PMID 27348086Read ↗

Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter "Real-Life" Experience.Semantic proximity Read ↗

Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis.Semantic proximity Read ↗

Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.Semantic proximity Read ↗

Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis.Semantic proximity Read ↗

Daclatasvir and Sofosbuvir With or Without Ribavirin in Liver Transplant Recipients: A Single-Center Real-World Study.Semantic proximity Read ↗

Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients.Semantic proximity Read ↗

Efficacy and safety of sofosbuvir-based interferon-free therapies for hepatitis C in liver transplant recipients.Semantic proximity Read ↗

Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?Semantic proximity Read ↗

Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.Semantic proximity Read ↗

Recurrent hepatitis C following liver transplant: diagnosis, natural history, and therapeutic options.Semantic proximity Read ↗

Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience.Semantic proximity Read ↗

Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.